Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 14/20 | 0.48 |
| ▸ | TMPRSS15 | P98073 | 14/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104411 | 0.85 | ITGB3 (0.69) | ITGB3ITGA2BPRSS1TMPRSS15 | |
| SCHEMBL7305759 | 0.84 | ITGB3 (0.54) | ITGB3ITGA2B | |
| SCHEMBL7306316 | 0.82 | ITGB3 (0.51) | ITGB3ITGA2BPRSS1TMPRSS15 | |
| Trifluoroacetic Acid SCHEMBL9217427 | 0.80 | ITGB3 (0.49) | ITGB3ITGA2B | |
| SCHEMBL9296637 | 0.78 | ITGB3 (0.46) | ITGB3ITGA2BPRSS1TMPRSS15 | |
| Trifluoroacetic Acid SCHEMBL7308419 | 0.77 | ITGB3 (0.46) | ITGB3ITGA2B | |
| SCHEMBL7338778 | 0.77 | ITGB3 (0.46) | ITGB3ITGA2BPRSS1TMPRSS15NPSR1 | |
| SCHEMBL7748657 | 0.77 | PRSS1 (0.71) | ITGB3ITGA2BPRSS1 | |
| SCHEMBL8830329 | 0.77 | ITGB3 (0.41) | ITGB3ITGA2BPRSS1TMPRSS15 | |
| SCHEMBL7441948 | 0.75 | EPHX2 (0.44) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20070189970-A1 | Contrast medium for thrombus formation | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070189970-A1 | Contrast medium for thrombus formation | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070189970-A1 | Contrast medium for thrombus formation | FGB, F13B, TFPI | ITGB3 36/4885ITGA2B 17/4885PRSS1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.